Login to Your Account



4SC Stock Plummets on Vidofludimus Miss in RA

By Cormac Sheridan


Thursday, June 9, 2011
Shares in 4SC AG dropped 36 percent Wednesday on news that its orally available drug vidofludimus missed the primary endpoint of a Phase IIb clinical trial in rheumatoid arthritis, dashing investor hopes of a near-term deal.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription